THE PROPERTY DEVELOPMENT REVIEW
In September of 2015, Dennis then acquired Arrow Pharmaceuticals in a c. $380m deal, later merging the business in July of 2019 with Apotex Australia to form Arrotex Pharmaceuticals, the business of which he leads today as Co-Founder, Chairman & Chief Executive Officer - a business which is now Australia’s largest generic drug supplier with over 1,260 products, over $2bn of sales and c. $200m per annum in earnings. Within the broader DBG Health portfolio, Dennis has also diversified his interests through a number of ventures including VidaCorp, which holds consumer, challenger and private label brands, Juno Pharmaceuticals, a supplier of specialist oncology and surgery drugs to healthcare institutions and MyDNA, a business which specialises in providing medical testing equipment. In this exclusive interview, Dennis takes us on a journey throughout his remarkable career, from the pivotal moments that led him into the healthcare and pharmaceutical industries, to the growth and evolution of DBG Health - along the way, exploring the key lessons, achievements, challenges, and successes that have led him to become one of Australia’s preeminent businesspeople.
September / October 2024 – 7
Powered by FlippingBook